P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy
2016
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
12
Citations
NaN
KQI